Abstract
B-cell lymphomas represent a heterogeneous collection of more than twenty-five different malignancies. Classification is often challenging as primarily based upon, sometimes subjective, histopathological criteria and misdiagnosis can result in inappropriate treatment decisions. MicroRNAs (miRNAs) hold great promise as novel biomarkers (diagnostic, prognostic and predictive) of B-cell lymphoma in addition to being potential therapeutic targets. The most promising of these miRNAs more often than not play key regulatory roles in lymphopoiesis (development of lymphocytes) when under physiological conditions, and in the pathology of lymphoid malignancies when aberrantly expressed. In this review we consider the identity and functional role of miRNAs in the most common forms of B-cell lymphomas, their role in lymphopoiesis and their potential as biomarkers for these malignancies.
Keywords: Biomarker, blood, diffuse large B cell lymphoma, lymphoma, lymphomagenesis, microRNA.
MicroRNA
Title:Aberrant Expression of MicroRNAs in B-cell Lymphomas
Volume: 5 Issue: 2
Author(s): Carla Sole, Erika Larrea, Lorea Manterola, Ibai Goicoechea, María Armesto, María Arestin, María M. Caffarel, Angela M. Araujo, Marta Fernandez-Mercado, María Araiz and Charles H. Lawrie
Affiliation:
Keywords: Biomarker, blood, diffuse large B cell lymphoma, lymphoma, lymphomagenesis, microRNA.
Abstract: B-cell lymphomas represent a heterogeneous collection of more than twenty-five different malignancies. Classification is often challenging as primarily based upon, sometimes subjective, histopathological criteria and misdiagnosis can result in inappropriate treatment decisions. MicroRNAs (miRNAs) hold great promise as novel biomarkers (diagnostic, prognostic and predictive) of B-cell lymphoma in addition to being potential therapeutic targets. The most promising of these miRNAs more often than not play key regulatory roles in lymphopoiesis (development of lymphocytes) when under physiological conditions, and in the pathology of lymphoid malignancies when aberrantly expressed. In this review we consider the identity and functional role of miRNAs in the most common forms of B-cell lymphomas, their role in lymphopoiesis and their potential as biomarkers for these malignancies.
Export Options
About this article
Cite this article as:
Sole Carla, Larrea Erika, Manterola Lorea, Goicoechea Ibai, Armesto María, Arestin María, Caffarel M. María, Araujo M. Angela, Fernandez-Mercado Marta, Araiz María and Lawrie H. Charles, Aberrant Expression of MicroRNAs in B-cell Lymphomas, MicroRNA 2016; 5 (2) . https://dx.doi.org/10.2174/2211536605666160825150830
DOI https://dx.doi.org/10.2174/2211536605666160825150830 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
Call for Papers in Thematic Issues
Modulatory Roles of Non-coding RNAs in cancer therapy
This thematic issue aims to elucidate the most recent research on ncRNAs in CRCs and discuss the importance and difficulties that may arise in applying this tool on a regular clinical basis.read more
Revolutionizing Animal Farming: The Impact of miRNAs on Health and Productivity
The utilization of microRNAs (miRNAs) in animal production represents an emerging frontier in agricultural biotechnology, with the potential to revolutionize the sector. MiRNAs, small non-coding RNA molecules, play a crucial role in regulating gene expression, influencing vital processes such as growth, muscle development, disease resistance, and feed efficiency. Their application ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanotechnology for Nanomedicine and Delivery of Drugs
Current Pharmaceutical Design Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors
Current Medicinal Chemistry Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry P-glycoprotein as a Drug Target in the Treatment of Multidrug Resistant Cancer
Current Drug Targets Multifunctional Materials for Cancer Therapy: From Antitumoral Agents to Innovative Administration
Current Organic Chemistry Potential Novel Targets in Breast Cancer
Current Pharmaceutical Biotechnology Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Applications of Umbilical Cord Derived Mesenchymal Stem Cells in Autoimmune and Immunological Disorders: From Literature to Clinical Practice
Current Stem Cell Research & Therapy Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Current Cancer Drug Targets Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review
Current Pharmaceutical Design Neutral Actions of Raltegravir on Adipogenesis, Glucose Metabolism and Lipolysis in 3T3-L1 Adipocytes
Current HIV Research Exosomes: A Promising Factor Involved in Cancer Hypoxic Microenvironments
Current Medicinal Chemistry Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism Targeting Gene Therapy for Prostate Cancer
Current Pharmaceutical Design Novel Chemotherapeutic Agents - The Contribution of Scorpionates
Current Medicinal Chemistry The Role of AMPK/mTOR Modulators in the Therapy of Acute Myeloid Leukemia
Current Medicinal Chemistry Signal Transduction Pathways and Transcriptional Mechanisms as Targets for Prevention of Emergence of Multidrug Resistance in Human Cancer Cells
Current Drug Targets Protein Kinases as Tumor Biomarkers and Therapeutic Targets
Current Pharmaceutical Design Positron Emission Tomography Imaging of Tumor Hypoxia
Current Medical Imaging